NEW YORK (GenomeWeb News) – Intrinsic Bioprobes will measure cancer-related proteins and peptides that may improve diagnostic capabilities for disease, under a two-and-a-half year contract with the National Cancer Institute, the company said today.
Under the agreement, Intrinsic Bioprobes will receive $1.1 million from NCI, while the company will provide $146,000 toward the project.
The contract will support NCI's Clinical Proteomic Technologies for Cancer initiative, which focuses on assessing and using proteomics technologies and data resources to solve critical problems in cancer research.
Intrinsic Bioprobes focuses on mass spectrometry-based assays and platforms for rapid biomarker analysis, and its technologies include the Mass Spectrometric Immunoassay and the Bioreactive Mass Spectrometer Probes. These technologies are used in the firm's Massay System, which is a high-throughput mass spectrometry platform for rapid proteome analysis.
"The purpose of this contract is to stimulate the development of multiplex mass spectrometric immunoassay for the detection of low abundance cancer-related proteins/peptides from bodily fluids," Intrinsic Bioprobes Scientific Director Dobrin Nedelkov said in a statement.
The mass spectrometric immunoassays will bridge the gap between the clinical use of proteomics tools and their science and research applications, Nedelkov added, saying that they are highly specific and selective, have ultra-sensitive detection capabilities and broad dynamic range, and require limited sample preparation.